Use of B. Licheniformis to Mitigate the Impact of Necrotic Enteritis On-Farm

reading time
Article | 01.04.2021
Wouter Van der Veken
Global Product Manager Feed Additives

Both clinical and sub-clinical gastrointestinal diseases in broilers can lead to poor welfare, reduced profitability and major losses on farm. Necrotic enteritis (NE) is a prominent example, with the opportunistic pathogen Clostridium perfringens being a causative agent in the onset and development of the disease.

On an economic level, the global cost of NE outbreaks has been estimated to be between 2-6 billion dollars annually. With the use of antibiotics under scrutiny, both in sub-therapeutic concentrations as well as in treatment dosages, various alternative feed additives have been developed to help mitigate NE in poultry flocks. 

Probiotics as a first security

An interesting example is probiotics, viable micro-organisms which, when administered in adequate amounts, confer health benefits to the host. Their mode of action is often multifactorial, with benefits coming from:

  • outcompeting pathogens for nutrients or physical space
  • producing beneficial compounds
  • increasing the digestion and/or adsorption of nutrients
  • improving the gut barrier function
  • reducing gut inflammation
  • interacting with the immune system
  • or a combination of the above

An example of a well-known probiotic to mitigate NE is Bacillus licheniformis, with the probiotic showing to be antagonistic against C. perfringens both in vivo and in vitro

More recent research has highlighted this further, confirming the probiotic's capability to reduce the negative effects caused by NE on the gut microbiota of chickens. To evaluate the above, a commercially available B. licheniformis, B-Act® (Huvepharma), was put to the test. The probiotic product is based on a single strain of B. licheniformis (DSM 28710), already known to support technical performance in poultry and inhibit C. perfringens

B. licheniformis versus induced NE

To confirm its efficacy in terms of mitigating induced NE, a 42-day trial was conducted in broilers. Both health and production performance parameters were recorded in the trial, which has been published in the Journal of Applied Animal Nutrition. 

The trial set-up included an induced NE challenge, with all animals receiving the same amount of C. perfringens on day 19, 20 and 21 (1.0 m;/bird, 1.0 x 108-9 CFU C. perfringens/ml). The C. perfringens strain used was known to have caused NE on-farm in the past. Over the course of the study, three groups were evaluated: a negative control (basal diet), a B-Act® group (1.6 x 1012 CFU B. licheniformis DSM 28710/tonne of feed, supplemented from start to finish) and an antibiotic group.

Animals in this latter group were treated with oxytetracycline hydrochloride (OXT; according to label recommendations), for three consecutive days after the NE challenge. Even under the induced NE challenge, weight gains of the B-Act® and OXT groups were similar to each other and significantly higher compared to the control at the end of the study (P<0.05). 

Weight gain in the B-Act® group was already significantly higher compared to the control on day 21 (P<0.05, Figure 1), indicating a potential benefit of the probiotic even before clinical establishment of NE. 

Figure 1. Technical performance for the three groups, from day 0-42. Different superscripts indicate significant differences (P<0.05).

Feed conversion ratio (FCR) values followed a similar pattern throughout the study, with a significantly lower overall FCR for the B-Act® and OXT groups compared to the control (P<0.05, Figure 1; day 0-42). 

From a health perspective, NE lesion scores, NE mortality and general mortality were also evaluated. For all three parameters, both B-Act® and OXT groups had significantly lower values than the control (P<0.05, Figure 2). 

Figure 2. NE lesion scores for the three groups, at day 21 and day 28. Different superscripts indicate significant differences (P<0.05).



This trial demonstrates that feeding probiotic B-Act® significantly improved both health as well as growth performance parameters of broilers under an NE challenge.

The results achieved with prophylactically administered B-Act® were comparable to those realized with the therapeutic OXT treatment. As such, continuous administration of B-Act® has the potential to be a useful and practical tool to mitigate NE in commercial broilers.


This article appeared in International Poultry Production Vol 29, No 2.
References are available on request
global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us


Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .




North America


South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.


United States

Click here to visit the local website or close this popup to stay on the global website.

Your browser is out of date!

Update your browser to view this website correctly. Update my browser now